Benzbromarone

證據等級: L5

預測適應症: 1 個

Benzbromarone: From Hyperuricemia/Gout to Renal Hypouricemia

One-Sentence Summary

Benzbromarone is a uricosuric agent (URAT1 inhibitor) originally used for the treatment of hyperuricemia and gout. The TxGNN model predicts it may be effective for Renal Hypouricemia, with 0 clinical trials and 20 publications identified—however, mechanistic analysis indicates this is a contra-indicated false positive: the drug would worsen, not treat, the predicted condition.

Quick Overview

Item	Content
Original Indication	Hyperuricemia / Gout (license detail unavailable)
Predicted New Indication	Hypouricemia, renal
TxGNN Prediction Score	99.07%
Evidence Level	L5 — Model prediction only; no therapeutic clinical evidence
Malaysia Market Status	✓ Marketed
Number of Registrations	1
Recommended Decision	Hold ⛔ (Mechanistic contradiction)

Why is This Prediction Reasonable?

Short answer: it is not. While the TxGNN model assigns a high confidence score (99.07%), deeper mechanistic analysis reveals this prediction is a classic false positive driven by pathway association without regard to therapeutic directionality.

Benzbromarone is a potent inhibitor of URAT1 (urate transporter 1, encoded by the SLC22A12 gene). Its pharmacological action blocks uric acid reabsorption in the renal proximal tubule, thereby promoting urinary uric acid excretion. This mechanism makes it effective for treating hyperuricemia and gout, where the therapeutic goal is to lower serum urate by increasing renal urate clearance.

Renal hypouricemia, by contrast, is an inherited disorder caused by loss-of-function mutations in URAT1 (SLC22A12) or GLUT9 (SLC2A9). Patients already have defective urate reabsorption, resulting in excessive urinary urate excretion and dangerously low serum urate levels. Administering benzbromarone—a drug that further inhibits the very transporter that is already dysfunctional—would exacerbate the condition rather than treat it. The TxGNN model correctly identified that benzbromarone and renal hypouricemia share the URAT1 pathway, but it cannot distinguish between “treats via this pathway” and “acts on the same pathway in the wrong direction.” This is a well-recognized limitation of knowledge graph–based drug repurposing models.

Clinical Trial Evidence

Currently no related clinical trials registered for benzbromarone in the treatment of renal hypouricemia.

Literature Evidence

Twenty publications were identified; however, none describe therapeutic use of benzbromarone for renal hypouricemia. Instead, benzbromarone appears exclusively as a diagnostic pharmacological probe used to characterize urate transport defects. The most relevant publications are summarized below:

PMID	Year	Type	Journal	Key Findings
31650389	2020	Review	Clin Rheumatol	Comprehensive review of hypouricemia for rheumatologists; classifies aetiologies and discusses URAT1/GLUT9 mutations. Benzbromarone mentioned as diagnostic tool only.
14694169	2004	Observational/Molecular	J Am Soc Nephrol	Sequenced SLC22A12 in 32 renal hypouricemia patients; established that URAT1 mutations cause the disorder. Benzbromarone used in tubular transport analysis.
14747372	2004	Preclinical/Mechanistic	J Am Soc Nephrol	Characterised mouse URAT1 homologue (RST); benzbromarone inhibited RST-mediated urate transport in Xenopus oocytes, confirming URAT1 inhibition mechanism.
18670416	2008	Pharmacological Study	Am J Hypertens	Demonstrated losartan’s uricosuric action via URAT1 inhibition in hypertensive patients; contextualises benzbromarone’s mechanism alongside other URAT1 inhibitors.
14655203	2003	Case Report	Am J Kidney Dis	Two siblings with hereditary renal hypouricemia and exercise-induced ARF; URAT1 mutation (W258X) identified. Benzbromarone used only in diagnostic workup.
8893184	1996	Pharmacological Study	Nephron	Analysed uric acid transport in Fanconi syndrome with marked renal hypouricemia using pyrazinamide and benzbromarone as pharmacological probes.
10879667	2000	Case Series	Clin Nephrol	Patient with recurrent exercise-induced ARF and renal hypouricemia; benzbromarone/pyrazinamide tests used to localise the tubular transport defect.
8863890	1996	Case Report	Acta Paediatr	Recurrent exercise-induced ARF in renal hypouricemia; benzbromarone/pyrazinamide test suggested defective presecretory reabsorption.
4009341	1985	Case Series	J Pediatr	Four children with hereditary renal hypouricemia; pyrazinamide and benzbromarone did not affect clearance ratios, consistent with severe transport defects.
3380222	1988	Case Report/Mechanistic	Nephron	Young man with isolated renal urate transport defect; urate clearance further increased after benzbromarone, confirming drug worsens the phenotype.

Key observation: In multiple case reports (PMIDs 3380222, 8863890, 4009341), benzbromarone administration increased urate clearance in hypouricemic patients—i.e., it made the condition worse. This directly confirms the mechanistic contraindication.

Malaysia Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
(Detail unavailable)	—	—	—

Note: One registration is recorded in Malaysia (market status: marketed), but detailed license information was not retrieved. Benzbromarone is internationally recognised as a uricosuric agent indicated for hyperuricemia and gout.

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data were not available in this evidence pack.

Important note specific to this prediction: Benzbromarone carries a known risk of hepatotoxicity (the reason it was withdrawn in several European markets). Additionally, in patients with renal hypouricemia, use of benzbromarone could theoretically precipitate exercise-induced acute renal failure by further increasing urinary uric acid excretion and promoting intratubular urate crystal deposition.

Conclusion and Next Steps

Decision: Hold ⛔

Rationale: This prediction represents a mechanistic false positive. The TxGNN model detected a strong association between benzbromarone and renal hypouricemia via the shared URAT1 pathway, yielding a high prediction score (99.07%). However, the drug’s pharmacological action (URAT1 inhibition → increased urate excretion) is diametrically opposed to what renal hypouricemia patients need (restored urate reabsorption → decreased urate excretion). Published case reports confirm that benzbromarone worsens urate clearance in these patients. This candidate should not proceed to any further evaluation stage.

This case highlights an important limitation of knowledge graph–based repurposing models: pathway-level association does not equate to therapeutic applicability. Directional pharmacological reasoning must be applied as a post-prediction filter.

No further action is recommended for this candidate. Instead, the following model improvement is suggested:

Incorporate directionality annotations (agonist/antagonist, gain-of-function/loss-of-function) into the TxGNN knowledge graph to reduce contra-indicated false positives
Flag candidates where the drug’s MOA targets the same transporter/receptor implicated in the disease’s loss-of-function aetiology
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.